Vanguard Group Inc Candel Therapeutics, Inc. Transaction History
Vanguard Group Inc
- $5.97 Trillion
- Q2 2025
A detailed history of Vanguard Group Inc transactions in Candel Therapeutics, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 1,787,549 shares of CADL stock, worth $9.89 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,787,549
Previous 1,736,104
2.96%
Holding current value
$9.89 Million
Previous $9.81 Million
7.79%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding CADL
# of Institutions
84Shares Held
15.3MCall Options Held
570KPut Options Held
203K-
Acorn Capital Advisors, LLC New York, NY2.58MShares$14.3 Million8.54% of portfolio
-
Northpond Ventures, LLC1.94MShares$10.7 Million48.35% of portfolio
-
Portolan Capital Management, LLC Boston, MA1.62MShares$8.97 Million0.59% of portfolio
-
Geode Capital Management, LLC Boston, MA904KShares$5 Million0.0% of portfolio
-
Black Rock Inc. New York, NY823KShares$4.55 Million0.0% of portfolio
About Candel Therapeutics, Inc.
- Ticker CADL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,891,900
- Market Cap $160M
- Description
- Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the...